Almirall Company Profile

✉ Email this page to a colleague

ALMIRALL has ten approved drugs.

There are twelve US patents protecting ALMIRALL drugs.

There are two hundred and sixteen patent family members on ALMIRALL drugs in thirty-four countries and seventeen supplementary protection certificates in ten countries.

International Patents:	216
US Patents:	12
Tradenames:	9
Ingredients:	8
NDAs:	10
Patent Litigation for Almirall:	See patent lawsuits for Almirall

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Almirall	ACZONE	dapsone	GEL;TOPICAL	021794-001	Jul 7, 2005	AB	RX	Yes	Yes		⤷ Start Trial				⤷ Start Trial
Almirall	SEYSARA	sarecycline hydrochloride	TABLET;ORAL	209521-003	Oct 1, 2018		RX	Yes	Yes	9,481,639	⤷ Start Trial				⤷ Start Trial
Almirall	KLISYRI	tirbanibulin	OINTMENT;TOPICAL	213189-001	Dec 14, 2020		RX	Yes	Yes	7,300,931	⤷ Start Trial	Y	Y		⤷ Start Trial
Almirall	TAZORAC	tazarotene	GEL;TOPICAL	020600-001	Jun 13, 1997	AB	RX	Yes	Yes		⤷ Start Trial				⤷ Start Trial
Almirall	SEYSARA	sarecycline hydrochloride	TABLET;ORAL	209521-002	Oct 1, 2018		RX	Yes	No	8,318,706	⤷ Start Trial	Y	Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Almirall	ACZONE	dapsone	GEL;TOPICAL	021794-001	Jul 7, 2005	6,060,085	⤷ Start Trial
Almirall	SOLAGE	mequinol; tretinoin	SOLUTION;TOPICAL	020922-001	Dec 10, 1999	5,194,247	⤷ Start Trial
Almirall	ALTABAX	retapamulin	OINTMENT;TOPICAL	022055-001	Apr 12, 2007	RE43390	⤷ Start Trial
Almirall	TAZORAC	tazarotene	GEL;TOPICAL	020600-002	Jun 13, 1997	5,914,334	⤷ Start Trial
Almirall	AVAGE	tazarotene	CREAM;TOPICAL	021184-003	Sep 30, 2002	5,089,509	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Gel	7.5%	➤ Subscribe	2017-02-13

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1028961	SPC/GB07/061	United Kingdom	⤷ Start Trial	PRODUCT NAME: RETAPAMULIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/390/001 20070524; UK EU/1/07/390/002 20070524; UK EU/1/07/390/003 20070524; UK EU/1/07/390/004 20070524
1836169	C01836169/01	Switzerland	⤷ Start Trial	FORMER OWNER: ATHENEX, INC., US
1836169	LUC00235	Luxembourg	⤷ Start Trial	PRODUCT NAME: KLISYRI - TIRBANIBULINE; AUTHORISATION NUMBER AND DATE:
1836169	SPC/GB22/002	United Kingdom	⤷ Start Trial	PRODUCT NAME: TIRBANIBULIN; REGISTERED: UK EU/1/21/1558(FOR NI) 20210719; UK FURTHER MA ON IPSUM 20210719
1836169	122021000066	Germany	⤷ Start Trial	PRODUCT NAME: KLISYRI TIRBANIBULIN; REGISTRATION NO/DATE: EU/1/21/1558 20210716
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.